Atlas Trials

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Clinical trial NCT04562766 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04562766
Sponsor
Principia Biopharma, a Sanofi Company
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2020-12-14
Primary completion
2025-01-15
Enrollment
232

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.